-
Mashup Score: 8
Introduction Stereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and the use of knowledge-based planning (KBP) to assess radiotherapy plan quality. Methods and analysis Eligible patients must have biopsy-proven unfavourable intermediate or favourable high-risk PC, have an Eastern Collaborative Oncology Group (ECOG) performance status 0-1 and provide written informed consent. All patients will receive 6 months in total of androgen deprivation therapy. Patients will be randomised to one of two SBRT regimens. The first will be 40 Gy in five fractions given on alternating days (SBRT monotherapy). The second will be 20 Gy in two fractions given 1 week apart followed
Source: bmjopen.bmj.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 4
PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
Breaking down the recurrences, only two were within the prostate, and several would potentially been picked up had we had access to #PSMA in 2014… https://t.co/dJvdJYRGZj https://t.co/yjsBRufRqd
-
-
Mashup Score: 4Frontiers | Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS) - 3 month(s) ago
Objectives: To report feasibility, early toxicity, and PSA kinetics following gantry-based, stereotactic radiotherapy (SBRT) boost within a prospective, phas…
Source: www.frontiersin.orgCategories: General Medicine News, Oncologists2Tweet-
151 men were accrued at 5 centres. We had a mixed population with the intention of showing wide applicability: 26% NCCN high risk, around half got 6-18 months ADT, and 10% whole pelvic radiotherapy. Link to interim data here: https://t.co/ptrdwmPgUA
-
-
Mashup Score: 3PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol - BMC Cancer - 3 month(s) ago
Background High Dose Rate Brachytherapy (HDRB) boost is a well-established treatment for prostate cancer (PC). We describe the PROstate Multicentre External beam radioTHErapy Using Stereotactic boost (PROMETHEUS) study. Non-surgical stereotactic techniques are used to deliver similar doses to HDRB boost regimens with a dose escalation sub-study. Methods Eligible patients have intermediate or high risk PC. PROMETHEUS explores the safety, efficacy and feasibility of multiple Australian centres cooperating in the delivery of Prostate Stereotactic Body Radiotherapy (SBRT) technology. A SBRT boost component Target Dose (TD) of 19Gy in two fractions is to be delivered, followed by a subsequent EBRT component of 46Gy in 23 fractions. Once accrual triggers have been met, SBRT doses can be escalated in 1 Gy increments to a maximum of 22Gy in two fractions. Patient safety will also be measured with the rate of both acute and late moderate to severe Gastro-Intestinal (GI) and Genito-Urinary (GU)
Source: bmccancer.biomedcentral.comCategories: General Medicine News, Oncologists2Tweet-
We explored virtual HDRB boosting using #SBRT. 19-20Gy in 2 fractions followed by either 46Gy/23# or 36Gy/12#. Link to protocol manuscript here: https://t.co/da8UOkxT7u
-
-
Mashup Score: 64Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial - 3 month(s) ago
Despite the high efficacy of high-dose-rate brachytherapy boost (HDRB) in the management of prostate cancer (PC), use of this approach is declining. S…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
How would you like to offer men with #prostatecancer a treatment proven to have ~95% disease control at 5 years? Results of our prospective multicentre PROMETHEUS clinical trial now out in @EurUrolOncol. Open access link here, and breakdown in thread. https://t.co/JgVRipRfWL
-
-
Mashup Score: 4A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer - 3 month(s) ago
Objective To characterize national clinical practice trends in the treatment of prostate cancer (PCa) in Australia. Patients and Methods Population-level data were extracted from existing Medicare…
Categories: General Medicine News, Oncologists2Tweet-
Brachytherapy boost gives excellent disease control, but due to difficulties with access and concerns about toxicity, its use is falling around the world. https://t.co/ePpY4MUlQM
-
-
Mashup Score: 0Genitourinary quality of life comparison between urethral sparing prostate SBRT monotherapy and virtual HDRB boost - 1 year(s) ago
Although radiation dose escalation improves prostate cancer disease control, it can cause increased toxicity. Genitourinary (GU) symptoms after prosta…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
Link to article: https://t.co/47MInJr9It
-
-
Mashup Score: 0
Introduction Stereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and…
Source: BMJ OpenCategories: Latest Headlines, Oncologists2Tweet-
Link to NINJA trial protocol: https://t.co/Taa4lLjDP5
-
-
Mashup Score: 0
Introduction Stereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and…
Source: BMJ OpenCategories: Latest Headlines, Oncologists2Tweet-
@alison_tree @DrOmarMian @TheLancetOncol @_ShankarSiva @lucindamorris23 @PBlanchardMD @piet_ost @sandraturner49 @stephane_supiot @TROGfightcancer @ANZUPtrials @DrSpratticus @ZilliThomas Thanks @alison_tree. Urethra_PRV D0.1cc<42Gy in our current NINJA protocol, but with VMAT only really comes into play when boosting a peripheral dominant lesion off-study. https://t.co/Taa4lLjDP5
-
-
Mashup Score: 1Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
Our review article in the latest @TheLancetOncol on 'Mechanisms, mitigation, and management of urinary toxicity from prostate #radiotherapy'. Now that GI issues are better controlled, this should be a key #survivorship focus. Let me know what you think. https://t.co/Xrxichz99w https://t.co/GZ3AzpWcWW
-
We are now comparing this promising regimen with 40Gy/5# on our NINJA RCT, expected to complete accrual in 2024. A similar approach is also being investigated as one of the randomisations in PEACE 7. https://t.co/3tGbD5iI7f